DIANA ACOSTA: Open Payments
NPI 1134681562 · WELLINGTON, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,140 in 66 payments from 12 companies in 2025. Trend: 2023 $1,783 · 2024 $1,770 · 2025 $1,140
Food & beverage: $1,140
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 13 | $228 |
| E.R. Squibb & Sons, L.L.C. | 14 | $203 |
| CVRx, Inc. | 15 | $178 |
| Bayer Healthcare Pharmaceuticals Inc. | 6 | $164 |
| Merck Sharp & Dohme LLC | 4 | $94 |
| Novartis Pharmaceuticals Corporation | 3 | $63 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $58 |
| Novo Nordisk Inc | 2 | $53 |
| Esperion Therapeutics, Inc. | 2 | $38 |
| PFIZER INC. | 1 | $27 |
Products named: REPATHA, CAMZYOS, Barostim Neo System, Kerendia, VERQUVO, LEQVIO, JARDIANCE, NEXLETOL.
Industry payments across FL — which companies pay providers there.
